Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Adaptimmune Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst A. He anticipates that the biotechnology company will earn ($0.18) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $3.50 price target on the stock. The consensus estimate for Adaptimmune Therapeutics' current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics' Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported $0.27 earnings per share for the quarter. The business had revenue of $128.23 million for the quarter, compared to analyst estimates of $58.00 million. Adaptimmune Therapeutics had a negative return on equity of 83.38% and a negative net margin of 25.43%.
A number of other equities analysts also recently issued reports on ADAP. StockNews.com downgraded Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday. Guggenheim lowered their price objective on Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $3.16.
Get Our Latest Analysis on Adaptimmune Therapeutics
Adaptimmune Therapeutics Stock Performance
Shares of NASDAQ ADAP remained flat at $0.59 during trading on Friday. The company's stock had a trading volume of 5,183,377 shares, compared to its average volume of 1,705,188. The firm has a market cap of $150.02 million, a PE ratio of -2.67 and a beta of 2.26. The company has a 50-day moving average price of $0.88 and a two-hundred day moving average price of $1.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.09 and a current ratio of 3.09. Adaptimmune Therapeutics has a twelve month low of $0.42 and a twelve month high of $2.05.
Institutional Investors Weigh In On Adaptimmune Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in ADAP. Jane Street Group LLC lifted its stake in Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock worth $166,000 after purchasing an additional 98,581 shares in the last quarter. FMR LLC grew its position in shares of Adaptimmune Therapeutics by 3.0% during the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock worth $1,655,000 after buying an additional 50,419 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of Adaptimmune Therapeutics by 10.7% in the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company's stock valued at $15,944,000 after purchasing an additional 1,626,657 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Adaptimmune Therapeutics in the third quarter valued at $95,000. Finally, Fullcircle Wealth LLC purchased a new stake in Adaptimmune Therapeutics during the third quarter worth approximately $33,000. 31.37% of the stock is owned by hedge funds and other institutional investors.
Adaptimmune Therapeutics Company Profile
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Stories
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
